These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23950631)

  • 21. Correlation of expression of hormone and HER2 receptors with various clinico-pathological prognostic parameters and with each other in malignant breast lesion.
    Mohanty SS
    Ann Diagn Pathol; 2021 Feb; 50():151659. PubMed ID: 33249360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic features predicting involvement of non- sentinel axillary lymph nodes in Iranian women with breast cancer.
    Moosavi SA; Abdirad A; Omranipour R; Hadji M; Razavi AE; Najafi M
    Asian Pac J Cancer Prev; 2014; 15(17):7049-54. PubMed ID: 25227789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
    González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
    Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and histopathological features of breast cancer in Jordan: Experience from a tertiary care hospital.
    Obeidat F; Ahram M; Al Khader A; Battah K; Alchalabi M; Melhem JM; Suleiman A
    J Pak Med Assoc; 2017 Aug; 67(8):1206-1212. PubMed ID: 28839305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
    Zhang J; Sun J; Ouyang T; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):185-9. PubMed ID: 26988823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in the progesterone receptor contents between familial breast cancers and sporadic breast cancers stratified by patient age.
    Fukutomi T; Akashi-Tanaka S
    Surg Today; 2001; 31(11):963-7. PubMed ID: 11766082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
    Ashraf M; Jha JK; Mukherjee N; Panda CK; Nayak S; Jadhav TS; Dikshit N; Nath NC; Chakraborty J; Biswas J
    J Indian Med Assoc; 2011 Dec; 109(12):873-8. PubMed ID: 23469566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer in Bedouin-Arab patients in southern Israel: epidemiologic and biologic features in comparison with Jewish patients.
    Lazarev I; Flaschner M; Geffen DB; Ariad S
    Asian Pac J Cancer Prev; 2014; 15(18):7533-7. PubMed ID: 25292024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 2552 consecutive patients.
    Majid S; Rydén L; Manjer J
    World J Surg Oncol; 2018 Mar; 16(1):54. PubMed ID: 29530065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
    Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
    Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological, Treatment and Event-Free Survival Characteristics in a Moroccan Population of Triple-Negative Breast Cancer.
    Mouh FZ; Slaoui M; Razine R; El Mzibri M; Amrani M
    Breast Cancer (Auckl); 2020; 14():1178223420906428. PubMed ID: 32425539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive parameters for internal mammary node drainage in patients with early breast cancer.
    Lukesova L; Vrana D; Gatek J; Koranda P; Cwiertka K; Radova L; Melichar B; Prouzova Z; Sramek V; Svach I
    Tumori; 2014; 100(3):254-8. PubMed ID: 25076234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
    Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
    BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients.
    Cutuli B; Cottu PH; Guastalla JP; Mechin H; Costa A; Jourdan R
    Breast Cancer Res Treat; 2006 Jan; 95(1):55-64. PubMed ID: 16261401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression of Ki67 and clinicopathological features in breast cancer].
    Wang B; Wang X; Wang J; Xuan L; Wang Z; Wang X; Gao J; Zhang H
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):273-5. PubMed ID: 24989913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India.
    Nabi MG; Ahangar A; Wahid MA; Kuchay S
    Niger J Clin Pract; 2015; 18(3):381-6. PubMed ID: 25772923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor, progesterone receptor, and nuclear size features in female breast cancer in Libya: correlation with clinical features and survival.
    Abdalla FB; Markus R; Buhmeida A; Boder J; Syrjänen K; Collan Y
    Anticancer Res; 2012 Aug; 32(8):3485-93. PubMed ID: 22843935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.